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Abstract  
Objective 
To conduct a meta-analysis investigating the prevalence of pain in people with bipolar disorder (BD).   
Method 
A systematic review and random effects meta-analysis searching major electronic databases from 
inception till 01/2014 in accordance with the PRISMA statement.  We included articles reporting 
quantitative data on the prevalence of pain in people with BD with or without a healthy control 
group.  Two independent authors conducted searches, extracted data and completed 
methodological quality assessment.   
Results 
Twenty two cross-sectional studies were included, representing 12,375,644 individuals (BD n 
=171,352, n controls=12,204,292).  The prevalence of pain in people with BD was 28.9% (95% 
CI=16.4-43.4%, BD n =171,352).  The relative risk (RR) of pain in BD compared to controls was 2.14 
(95%CI=1.67-2.75, n=12,342,577).  The prevalence of migraine was 14.2% (95% CI = 10.6 - 18.3%, BD 
n=127,905) and the RR was 3.30 (95% CI=2.27-4.80, n=6,732,220).  23.7% (95% CI = 13.1-36.3%, 
n=106,214) of people with BD experienced chronic pain.  Age, percentage of males, methodological 
quality and method of BD classification did not explain the observed heterogeneity.   
Conclusion 
People with BD experience significantly increased levels of pain (particularly chronic pain and 
migraine). The assessment and treatment of pain should form an integral part of the management of 
BD. 
Key words: Pain, chronic pain. Migraine, bipolar disorder, severe mental illness  
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Summations 
 The pooled prevalence of clinical pain in people with bipolar disorder is approximately 
28.9%, whilst 23.7% and 14.2% are affected by chronic pain and migraines respectively.   
 Compared to the general population, people with bipolar disorder are at significantly 
increased risk of reported clinically relevant pain (Relative Risk= 2.14) and migraine (RR = 
3.30).   
 Since pain has a range of deleterious impacts on an individual’s health and quality of life and 
may worsen psychiatric symptoms, we recommend that pain assessment and treatment 
should form part of the routine care of people with bipolar disorder.  
Considerations 
 There was inconsistency in the assessment methods used to measure pain across the 
studies.   
 There was considerable heterogeneity in each of the pooled analysis that could not be 
explained by mean age, percentage of males, method of diagnosing bipolar disorder and 
methodological quality of the included studies.  
 There was insufficient information to determine the influence of the phase of illness and 
polarity as well as acuity of bipolar symptoms on the observed results.   
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Introduction 
Pain has a deleterious impact on an individual’s health and wellbeing (1) and common 
painful conditions, such as chronic musculoskeletal disorders, contribute to a significant number of 
years lived with disability across the globe (2). Chronic pain in particular is associated with greatly 
reduced quality of life, difficulties with activities of daily living (ADL), and often has a negative impact 
on an individual’s emotional and mental health (3).  A substantial body of literature suggests that 
those with chronic pain have higher rates of depressive and anxiety symptoms than those without 
chronic pain (4-6).   
Despite this, the prevalence of chronic pain in persons with severe mental illness (SMI) has 
received little attention (7, 8). This is surprising as persons with SMI such schizophrenia and bipolar 
disorder have a highly increased risk for a plethora of painful physical illnesses including 
cardiopulmonary diseases, metabolic diseases, bone disorders, viral infections, and cancer (9-12). In 
addition, pain in people with SMI is also associated with a worsening of psychiatric symptoms (7). 
Despite this increased risk of severe co-morbid physical illnesses, most persons with SMI do not 
receive adequate physical healthcare provision and treatment (13-15). Mental health specialists 
report barriers limiting their ability to treat physical co-morbidity and people with SMI are less likely 
to recognize or monitor co-occurring medical conditions than the general population (16, 17).  
Additionally many healthcare professionals fail to take people with severe mental illness seriously 
when they report physical health problems (18).  When compared to those without SMI, persons 
with SMI appear to have an increased likelihood of experiencing conditions that cause pain whilst at 
the same time having a lower likelihood of receiving adequate care to manage it (9, 10).  
 
A recent systematic review established that people with schizophrenia, who have been 
known to have a higher pain threshold for pain than the general population, have a lower 
prevalence of pain than people with other psychiatric disorders, particularly compared to those with 
bipolar disorder (19).  However, to date, no systematic review or meta-analysis of pain in individuals 
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with bipolar disorder exists, despite the fact this group appears to be particularly more likely to 
experience chronic pain and less likely to seek medical help (8). In fact, people with bipolar disorder 
reported almost 4 pain complaints at any one time (20). Moreover, people with bipolar disorder who 
are treatment adherent report statistically lower levels of pain than their non-treatment adherent 
counterparts (21).  Clearly, a better understanding of the risk and burden of pain is an important 
step toward improving clinical outcomes for individuals with bipolar disorder.  
Aims of the study 
In recognition of the potential for pain to be problematic for people with bipolar disorder, the paper 
had the following two aims: (1) to establish the prevalence of pain and its moderators in people with 
bipolar disorder, and (2) to compare the prevalence of pain in bipolar disorder with general 
population controls.    
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Method 
This systematic review was conducted according to the PRISMA statement (22) following a 
predetermined, but unpublished protocol.   
Inclusion and exclusion criteria 
Studies were eligible that fulfilled the following criteria: (1) inclusion of participants with bipolar 
disorder, diagnosed according to diagnostic criteria (e.g. DSM IV (23) or ICD 10 (24)), a valid 
screening measure (e.g., Alcohol Use Disorder and Associated Disabilities Interview Schedule—DSM-
IV Version) or through medical record review.  When we encountered studies containing groups of 
mixed participants (e.g., with major depressive disorder), we contacted the authors up to two times 
over a month period to ascertain the variables of interest in bipolar disorder subjects. If these data 
were not available, we excluded the study. (2) Reporting of the prevalence of pain (of any type) or 
assessment of pain with a continuous measure with or without comparison to a control group that 
did not have a mental illness. When a study measured pain with a continuous measure, but did not 
specify prevalence rates with a cut-off point, we contacted the authors up to two times to obtain 
this information.  
We did not place a language restriction upon our searches. If we came across studies that 
reported data from the same sample at different time points, we used the most recent data and/ or 
the largest data set. We excluded studies that (1) reported pain as an adverse event of a drug trial 
(e.g., for headache), (2) reported the prevalence of bipolar disorder in a sample of patients who all 
had pain (no other comorbidities were excluded), or (3) in which the pain was experimentally 
induced. When we encountered studies without a control group that assessed pain in a sample with 
a continuous measure (e.g., SF 36 bodily pain scale, (25)), but did not have a cut-off to determine the 
prevalence of pain, we excluded the study if the authors did not respond to requests for additional 
data. 
 
Information sources 
7 
 
Two reviewers (BS, DV) independently conducted searches on Academic Search Premier, MEDLINE, 
EMBASE, Psychology and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and 
Pubmed. In addition, the reference lists of all eligible articles and recent systematic reviews of the 
literature were scanned to assess eligibility of additional studies.  
 
Searches 
Two independent reviewers (BS, DV) employed the predetermined search strategy using the key 
words ‘bipolar disorder’ and ‘pain’ or ‘pain perception’ or ‘pain management’ or ‘pain measurement’ 
or ‘musculoskeletal pain’ or ‘pain intensity’ or ‘chronic pain’ or ‘neuropathic pain’ or ‘pain*’.   
 
Study Selection 
After the removal of duplicates, two independent reviewers (BS, DV) screened the titles and 
abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of 
full text articles was developed through consensus. Two reviewers (BS, DV) then considered the full 
texts of these articles and the final list of included articles was reached through consensus.   
 
Data Extraction 
Two authors (BS, DV) independently conducted data extraction using a predetermined form. The 
data collected from each article included: study design, geographical location, bipolar sample and 
control sample characteristics (number, % male, mean age), bipolar diagnosis method, method of 
pain assessment (including site, severity, and interference of pain where available) and the 
prevalence of pain in people with bipolar disorder and controls as defined by the authors.  
 
Methodological quality assessment  
Two independent authors (BS, DV) completed methodological quality assessment of included articles 
using the Newcastle Ottawa Scale (NOS; (26)). Due to the anticipated paucity of data, we also 
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included studies without a control group. These studies were considered as case control studies for 
the purposes of methodological assessment in accordance with a previous review (27).  The NOS is 
utilised to assess the methodological quality of non-randomised trials and has acceptable validity 
and reliability (26). The assessment tool focuses on three main methodological features: (1) the 
selection of the groups, (2) the comparability of the groups and (3) the ascertainment of the 
outcome of interest. The NOS can be modified and we adapted the NOS to take into account age and 
gender as comparability measures and considered pain assessment in the exposure category.  
Studies are given a score from 0-9, with a score of 5 or greater being indicative of satisfactory 
methodological quality.  We anticipated studies without a control group would score below this and 
present their results with due consideration.   
 
Meta-analysis 
We pooled individual study data using DerSimonian- Laird proportion method (28).  Our 
predetermined protocol stipulated that heterogeneity would be assessed with the Cochran Q 
statistic (29).  Since we found significant heterogeneity (Cochran Q = 66988.29 (df = 24) P < 0.0001) a 
random effects meta-analysis was employed using StatsDirect.  We calculated the relative risk (RR) 
to investigate the differences in pain between those with bipolar disorder and members of the 
general population when there were three or more studies (Aim 2).  When possible, we conducted 
subgroup analyses to investigate the prevalence of migraine and chronic pain since the literature has 
suggested these are prevalent in people with bipolar disorder (8).  In order to investigate sources of 
heterogeneity, we conducted moderator analysis with mean age, percentage of males, NOS score 
and the method of bipolar disorder classification (comparing DSIM, ICD or any other screening 
measure). We assessed publication bias with a visual inspection of funnel plots, yet gave priority to 
quantitative testing through the Begg-Mazumdar Kendall's tau (30) and Egger bias tests (31).   
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Results 
Study selection 
The original search yielded 2,713 potential hits which were reduced to 2,319 after the removal of 
duplicates.  At the eligibility screening stage, a total of 72 articles were deemed potentially eligible 
and full texts were obtained and reviewed by two authors. In total, 50 articles were excluded with 
reasons and 22 articles met the eligibility criteria and were included in the review (8, 32-52). The full 
search strategy including reasons for exclusion is presented in figure 1. 
Inset figure 1 about here 
Study characteristics 
In total 171,352 people with bipolar disorder and 12,204,292 general population controls (total 
sample size = 12,375,644) were included in the 22 meta-analysed studies. Details of the included 
studies are presented in table 1. All of the studies adopted a cross-sectional measurement of pain 
and 7 of these (n with bipolar disorder = 138,285; (8, 33, 38, 41, 44, 49, 52)) had a control group 
without a mental illness. The sample size of persons with bipolar disorder across the studies ranged 
from 10 (40) to 96,186 (8) and the control populations ranged from 32,333 (44) to 4,247,684 (8). The 
mean age of participants with bipolar disorder ranged from 39 (34) to over 65 years (51).   
 
Methodological quality 
The NOS summary score for each article is presented in table 1. All seven studies that had a control 
group scored high (mean NOS score 7.2±0.48) and were considered good quality. The 15 studies that 
did not have a control group all scored lower than 5 on the NOS, which was attributable to the 
absence of a control group; these studies scored zero (out of a possible 5 points) in the areas that 
compare the bipolar and control groups on selection, comparability, and exposure. 
 
Measurement and location of pain in the bipolar populations 
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A range of different types of pain were considered. The most commonly investigated pain was 
headache/migraine (8, 32, 33, 35, 39, 40, 42-44, 47, 52) whilst six studies investigated chronic pain 
(8, 34, 45, 48-50). A wide range of methods were employed to ascertain pain in people with bipolar 
disorder and are presented in table 1.   
Insert table 1 about here 
 
Prevalence of pain in persons with bipolar disease  
In total, 25 types of pain were investigated and the pooled prevalence of pain was 28.9% (95% CI: 
16.4-43.4%, n=171,352, Cochran Q = 66988.29 (df = 24) P < 0.0001, figure 2a).  The funnel plot was 
asymmetrical (figure 2b), however, both the Begg-Mazumdar (Kendall's tau = -0.013; P = 0.908) and 
Egger bias (Kendall's tau = 11.51; P = 0.4897) tests did not demonstrate any evidence of publication 
bias.  Next, we pooled the prevalence of pain using only one pain measurement from each of the 22 
studies, thus including only the highest prevalence of pain from 3 studies that contained data on 
pain at two sites (33, 35, 43). The prevalence of clinical pain across 22 studies was 28.4% (95% CI = 
15.0-44.1%, Cochran Q =66477.17 (df = 21) P < 0.0001).  Within this analysis, there was also no 
evidence of publication bias (Egger: bias = 12.44, P = 0.5176, Begg-Mazumdar: Kendall's tau = 0.021, 
P = 0.9113).   
Insert figure 2a and b about here 
Moderators of the prevalence of pain in people with bipolar disorder 
Ten studies (32-36, 38, 41, 42, 45, 49) had sufficient data on mean age, percentage of males and 
bipolar diagnosis method to enable moderator analyses.  The moderator analyses demonstrated 
that mean age (b1 = -0.038, z = -0.311, P = 0.75), % male (b2 = -0.074, z = -1.013, P = 0.311) and 
method of diagnosing bipolar disorder (b3 = -0.0935, z = -0.092, P = 0.92) did not explain the 
heterogeneity in the prevalence of pain. We investigated the effect methodological quality (NOS 
score) on the prevalence of pain across the 22 studies and this suggested that a low NOS score was 
associated with a high prevalence of pain but this did not reach statistical significance (b1=0.532, 
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z=1.875, p=0.06).  Lastly, we investigated the influence of the method of bipolar disorder diagnosis 
on the prevalence across all studies and this demonstrated that the classification used to diagnose 
bipolar disorder had no significant effect on the prevalence of pain (b1=0.310, z = 0.524, P = 0.59).   
 
Comparing the prevalence of pain in people with bipolar disorder versus control groups 
In each of the 7 studies with a control group, persons with bipolar disease consistently reported a 
higher prevalence of pain than the comparison group.  One study (33) provided pain data for two 
different types of pain and was corrected for multiple comparisons in the pooled analysis.  In total, 
data from 12,342,577 unique individuals (n with bipolar disorder =138,285 and control n= 
12,204,292) indicated that the relative risk of pain in people with bipolar disorder was 2.14 (95% CI = 
1.67 - 2.75 , Chi-square = 36.623  (df = 1)  P < 0.0001; Cochran Q = 1078.49 (df = 7) P < 0.0001).  The 
results from the meta-analysis are presented in figure 3. The funnel plot of the 7 included studies 
was not symmetrical indicating possible publication bias. However, the Eggers test (10.931 P = 
0.013), but not the Begg Mazumdar: test (Kendall's tau = 0.14; P = 0.7195) showed evidence of 
publication bias.   
 
Insert figure 3 about here 
Pooled prevalence of Migraine in people with bipolar disorder 
We also calculated the pooled prevalence of migraine in 127,905 individuals across 9 studies (8, 32, 
39, 40, 42-44, 47, 52) and this yielded a prevalence of 14.2% (95% CI = 10.6% - 18.3%; Cochran Q = 
1080.29 (df = 8) P < 0.0001).   
 
Comparing the prevalence of migraine in people with bipolar disorder versus control groups 
It was possible to pool the data from 3 comparative studies (8, 44, 52) involving 6,732,220 unique 
individuals (n with bipolar disorder=126,956, n controls = 6,605,264).  The RR was 3.30 (95% CI=2.27-
4.80, Chi-square test = 39.408 (df = 1) P < 0.0001).   
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Pooled prevalence of chronic pain in people with bipolar disorder 
It was possible to calculate the pooled prevalence of chronic pain in 106,214 individuals with bipolar 
disorder across 6 studies (8, 34, 45, 48-50).  The pooled prevalence of chronic pain was 23.7% (95% 
CI = 13.1-36.3, Cochran Q= 2200.77 (df = 5) P < 0.0001).  Only two comparative studies (8, 49) 
contained data on chronic pain and it was therefore not possible to meta-analyse these data.   
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Discussion 
To our knowledge this is the first systematic review and meta-analysis investigating the 
prevalence of pain in people with bipolar disorder. In this large review involving 171,352 persons 
with bipolar disorder and 12,204,292 controls, we found that a substantial proportion of patients 
with bipolar disorder reported clinically relevant levels of pain.  The overall pooled analysis of pain in 
people with bipolar disorder was 28.9% and the relative risk was over double for people with bipolar 
disorder compared to members of the general population. In terms of specific types of pain, the 
pooled prevalence of chronic pain was high with almost one in four (23.7%) being affected. In 
addition, migraine affected one in seven (14.2%) persons with bipolar disorder and the comparative 
analysis demonstrated that people with bipolar disorder are over three times more likely to 
experience migraines than members of the general population.   
 
Increased levels of pain in persons with bipolar disorder may be explained by several 
mechanisms. For instance, bipolar disorder and migraine appear to share some specific 
polymorphisms, with the KIAA0564 gene being particularly implicated, thus suggesting a close 
association (53, 54).  Also, people with bipolar disorder have an increased prevalence of depression 
(8, 36), and depression has been associated with increased physical complaints, and, possibly, 
greater pain sensitivity (55), opposite to findings in schizophrenia (19). For example, neuroimaging 
studies in major depressive disorder indicate that heightened amygdala activity, in part, explains the 
high comorbidity of pain and depression when these conditions become chronic (56).  However, due 
to limitations in the available data, we could not investigate the influence of depressive symptoms 
on the observed results. Other studies have suggested seretonergic and noradrenergic pathway 
involvement (7, 57).  In addition, specific neuroinflammatory mechanisms responsible for an 
elevated risk of painful physical comorbidity in people with bipolar disorder may contribute to the 
higher levels of observed pain (58).  Previous research (59) has found that migraine and bipolar 
disorder symptoms are closely related and the presence of migraine can influence pain perception.  
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Since we found that 14.2% of people with bipolar disorder experienced migraine, this could have 
influenced the variance in the prevalence of pain.  Lastly, recent findings (60) also suggest that 
limited cognitive flexibility and memory capacities may be linked to the mechanisms of pain 
chronicity and probably also to its neuropathic quality. This may imply that people with bipolar 
disorder who are known to have deficits in executive functioning or memory have a greater risk of 
pain chronicity after a painful event.  This seems particularly pertinent given the fact that we found 
across 106,214 individuals with bipolar disorder that almost one in four is affected by chronic pain.   
 
Clinical implications 
The results of this review are concerning since pain and in particular chronic pain in people 
with bipolar disorder is associated with impaired recovery (45), greater functional incapacitation (44, 
61), lower quality of life (8), and increased risk of suicide compared to people without pain (62).  
Since bipolar disorder is already associated with a greatly increased risk of suicide (63), it is 
imperative that this population receives adequate pain assessment and management (36). A central 
component to this is the training and education of psychiatrists who are in a critical place to oversee 
the pharmacological management of pain (7).  We advocate that systematic assessment of pain 
should be undertaken as part of the management of bipolar disorders, and that pain should be 
monitored during the course of treatment.  Equally, healthcare professionals dealing with pain 
should consider mental health complications. Previous work suggests clinicians are more likely to 
attend to pain than mental distress (64). The potential benefits of early identification and treatment 
of pain may not only include a reduction in pain and of its impact on the individual, but may also 
extend to a reduction of health-care costs and improvement of mental health outcomes.   
 
Of great concern are the high levels of chronic pain experienced by people with bipolar 
disorder.  A better understanding of the association of bipolar disorder and chronic pain could help 
limit harmful/adverse pharmacological side effects.  For instance, in the general population chronic 
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pain is often managed with tri-cyclical antidepressants (65), yet prescription of such medication to a 
person with bipolar disorder may inadvertently trigger a manic phase of illness if prescribed in the 
absence of a mood stabilizer (66). Commonly used analgesic medications also need careful 
consideration. For instance, there is sound evidence that non-steroidal anti-inflammatory 
medications can increase serum lithium levels, impairing renal lithium excretion and possibly 
eliciting lithium toxicity (67).  Similarly, some stronger analgesic medications such as opioids may 
have mood altering qualities increasing the risk of eliciting a manic episode (68).   
 
Limitations of the review 
Several limitations, especially of the included literature need to be considered when 
interpreting the results of our review. First, bipolar disorder is a complex and heterogeneous 
disorder, and reporting of pain likely varies according to different phases, polarity and acuity of the 
disease.  The paucity of information regarding these illness characteristics made it impossible to 
systematically evaluate their effects on pain prevalence in patients with bipolar disorder.  In 
addition, the perception and therefore prevalence of pain is known to vary according to the type of 
bipolar disorder (I or II; (59)) but due to limitations in the data we were not able to disentangle this 
relationship.  In addition, gender may also cause some variance, but our moderator analysis did not 
elucidate any evidence of a gender effect. Second, all of the included studies utilised a cross-
sectional measurement of pain and did not correlate pain with mood state or severity of symptoms. 
Therefore, prospective longitudinal studies that assess pain prevalence and severity over time and in 
relationship to mood symptoms and treatments are essential. Third, our results may have been 
suspect to Berkson’s bias, which states that clinical samples are more impaired and experience more 
pain than non-clinical samples due to self-referral to a clinical setting.  Berkson’s bias has been 
observed in the mood dimensions of bipolar disorder (69) and may account for an underreporting 
within the pooling of epidemiological data.  Fourth, none of the included studies used a validated 
pain assessment scale and subsequently information about the severity, location, variability, and 
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interference of pain during activities is lacking.  Fifth, all of the meta-analytic results were 
heterogeneous and some demonstrated a degree of publication bias.  In our moderator analysis, we 
were not able to explain the heterogeneity with mean age, % males, or the methodological quality of 
method of classification of bipolar disorder. This finding demonstrates that unknown/unmeasured 
factors contribute to the observed heterogeneity.  Regarding publication bias, the funnel plot for the 
main analysis (figure 2b) appeared asymmetrical, yet the quantitative investigation of bias did not 
demonstrate any evidence to support this.  This discrepancy may be due to the fact that there is a 
trend for publication bias, but its magnitude is insufficient to reach statistical significance according 
to the Eggers test or Begg-Mazumdar test.  In addition, the comparative analysis (figure 3) 
demonstrated some publication bias with the Eggers test, but this finding should be interpreted with 
caution due to the low number of studies (<10 (70)). Sixth, there was insufficient information about 
psychotropic and analgesic medication within the bipolar disorder cohorts to enable statistical 
investigation of these variables on the observed results.  Future research should seek to investigate 
the influence of psychotropic and analgesic medications on pain and particular attention should be 
paid to the prevalence of pain in people with bipolar disorder who are drug naïve.  In the same way, 
future research should investigate the role of psychiatric co-morbidities including anxiety and 
substance use disorders on the prevalence of clinical pain in these patients.  Finally, we included 15 
studies that received low methodological quality ratings.  However, the low methodological quality 
ratings were due to the absence of a control group, and the moderator analysis demonstrated that 
these studies had no significant effect on the observed results. Despite the aforementioned, higher 
levels of pain were reported consistently among people with bipolar disorder than in the comparison 
groups.   
 
Future research 
It is essential that future research seeks to clearly assess pain characteristics including noting 
the site, severity, variability and chronicity. There were insufficient data to analyse these pain 
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characteristics in our meta-analysis.  In addition, only one study (8) measured psychogenic pain and 
it would be important to investigate if this differs from physiological pain in people with bipolar 
disorder.  An important question, also unaddressed, is what is the impact of comorbid pain, 
particularly chronic pain, on daily activities? It is likely that chronic pain amplifies the effect of 
bipolar disorder on disability and reduced quality of life. Future prospective studies should be 
conducted in order to truly capture the prevalence of pain and disentangle its impact and 
contributing factors.  Such research should establish how pain impacts on a person’s mental health 
and wellbeing, with longitudinal studies being most important.  Future research should also explore 
the extent to which those with bipolar disorder are more or less responsive to behavioral, 
pharmacological, and non-pharmacological treatments for pain. For example, studies have not yet 
examined the impact on pain of anti-epileptic medications such as lamotrigine, valproate and 
topiramate among persons with bipolar disorder.  In addition, in the general population the 
promotion of physical activity is a key factor preventing the onset of chronic pain but is also 
encouraged to treat it (71) and many people with chronic pain are inactive (72).  However, research 
(73) has established that most people with bipolar disorder are sedentary. Therefore, strategies to 
encourage people with bipolar disorder to become active that do not exacerbate their pain are likely 
to be key in the prevention and management of pain and physical therapists can lead this process 
(74).  In addition, the barriers and facilitators to pain management should be explored in people with 
bipolar disorder with emphasis on the perspective of the patient and the treating multidisciplinary 
team.  Lastly, within our review, there were limited studies assessing pain in patients with bipolar 
disorder and those with other psychiatric conditions, making it impossible to directly compare the 
prevalence of clinical pain in people with bipolar disorder and other psychiatric diagnosis.  More 
research is required to directly compare clinical pain across different psychiatric disorders.   
 
Conclusion 
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Almost 30% of persons with bipolar disorder experience clinically relevant pain, which was twice as 
common compared to general population controls.  Chronic pain was prevalent affecting almost one 
in four people, and migraine was over 3 times as common than in the general population.  Pain has a 
range of adverse and deleterious impact upon the individual and may impede recovery, reduce 
quality of life and have adverse effects on psychiatric symptoms. Therefore, it is essential that 
treating psychiatrists and the wider multidisciplinary team seek to provide adequate assessment and 
treatment of pain in people with bipolar disorders.   
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Table 1 Included study characteristics and methodological quality 
Study No Location and design Bipolar diagnosis Participant with BD 
characteristics 
Control participant 
characteristics 
NOS 
score 
8 USA 
Cross sectional design 
collecting data over 1 
year 
ICD-9-CM 
Derived from patient 
electronic medical 
records 
N=96,186 
Age <35->80 years 
Males 81,757 (85.0%) 
No data on BD severity or 
medication 
N=4,247,684 
Age <35->80 years 
Males 3,882,806 (91.4%) 
7 
32 Brazil 
Cross sectional 
DSM IV N= 339 split in two groups 
Migraine (n=115) 
41.6 ±11.20 years 
Males 16 (17.4%) 
None migraine (n=224) 
41.5 ±12.32 years 
Male 60 (26.7%).  
 
No control group 3 
33 USA 
Cross sectional study 
collecting data over 5 
year period 
 
ICD-9 N= 3,557 
39.3 ±11.8 years 
Males 1395 (39.2%). 
BD more likely have 
substance use disorder OR 
2.92; (95% CI, 2.59 –3.29) 
& alcohol use disorder AOR 
19.63; (95% CI, 17.59-
21.90) 
N= 726,262 
37.7±12.8 years 
Male 345,146 (47.5%) 
 
7 
34 USA 
Cross sectional 
Composite International 
Diagnostic Interview 
Version 3.0 
N=740 
39 (±10.6) years 
Males 414 (56%)  
No data on BD severity or 
medication 
No control group 3 
  
Table 1 Included study characteristics and methodological quality 
Study Location and design Bipolar diagnosis Participant with BD 
characteristics 
Control participant 
characteristics 
NOS 
score 
35 Australia 
Cross sectional 
DSM IV N=67 
Males 35.8% (n=24) 
40.4 (±13.5) years 
BDRS= 11.5 ± 9.3 
No control group 
 
 
3 
36 Spain 
Cross sectional 
DSM-IV-TR N=121 
50.7 years (± 12.3) 
Males 45 (37.8%) 
50.7% had suicidal ideation 
No control group 3 
 
37 Italy 
Cross sectional 
 
DSM-IV-TR N= 248 
Demographic information 
not available  
 
No control group 3 
38 USA 
Cross sectional 
AUDADIS-IV N=883 
36.9±0.3 years 
Males 380 (43%) 
N= 42,210 
45.4±0.1 years 
Males 20,261 (48%) 
 
7 
39 UK 
Cross sectional 
retrospective 
Not stated N=169 
Demographic information 
not available  
 
No control group 3 
40 Taiwan  
Cross sectional  
DSM-IV-TR N=10 
Demographic data not 
available 
 
No control group 3 
41 USA 
Cross sectional 
retrospective analysis of 
data over 1 year 
 
ICD-9 medical records N=4,310 
Males 3879 (90%) 
53±13 years 
BD more likely have SUD 
(p<.0001) 
N=3,408,760 
Males 3,067,884 (90%) 
58 years 
8 
  
Table 1 Included study characteristics and methodological quality 
Study Location and design Bipolar diagnosis Participant with BD 
characteristics 
Control participant 
characteristics 
NOS 
score 
42 USA 
Cross sectional 
DSM IV N=111 
44.8±13.2 years 
Males 35 (32.4%) 
 
No control group 3 
43 Italy 
Cross sectional 
DSM III N= 30 
Demographic data not 
available 
 
No control group 3 
44 Canada 
Cross sectional 
CIDI N= 938 
Age 25-64 years 
Males 436 (46.4%) 
N=32,333 
Demographic information 
not available 
 
7 
45 USA 
Cross sectional (baseline 
from RCT) 
ICD-9 criteria N= 384 
42.07±11.3 years 
Males 128 (33.3%) 
 
 
No control group 3 
46 Australia 
Cross sectional 
ICD 9 N= 27  
10 males (37.0%) 
No control group 3 
47 Canada 
Cross sectional 
DSM IV N=296 with BD 1 and BD 2 
49.8 ± 12.7 years 
% males not available 
 
No control group 3 
48 South Korea  
Cross sectional 
DSM-IV N=190 
Demographic data not 
available 
 
 
No control group  3 
  
Table 1 Included study characteristics and methodological quality 
Study Location and design Bipolar diagnosis Participant with BD 
characteristics 
Control participant 
characteristics 
NOS 
score 
49 Scotland 
Cross sectional 
retrospective analysis 
 
GP databases N=2,582 
54.5 years 
Males 1,021 (39.5%) 
 
N=1,421,796 
47.9 years (p<0.001) 
Males 698,408 (49.1%) 
 
8 
50 Singapore 
Cross sectional 
 
CIDI 3.0 N=93 
Age 18-65> years 
Males 47 (50.5%) 
66% BD I -had severe or 
moderate manic/ 
hypomanic & 100% 
respondents with BP-II 
reported mild clinical 
severity on the YMRS 
Not reported 3 
51 United States 
Cross sectional 
ICD 9 N= 24206 
All >65 years nursing home 
residents 
No specific data on 
demographics  
No control group 3 
52 United States 
Cross sectional 
retrospective analysis 
ICD 9 N=27,054 
Demographics not 
available 
N=2,325,247 
Demographics not 
available 
8 
 
Key: BD = bipolar disease, GP=General practitioner, ICD-9-CM=International Classification of Diseases, 9th Revision, Clinical Modification, DSM-IV-
TR=Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, CIDI 3.0 = World Mental Health Composite International Diagnostic 
Interview version 3.0, AUDADIS-IV=NIAAA Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version, NOS = Newcastle Ottawa 
Scale, BDRS = Bipolar Depression Rating Scale, YMRS= Young Mania Rating Scale 
Table 2 Results of Pain in included studies  
Study Type of pain  Method of pain 
assessment/ 
ascertainment 
Pain results bipolar 
disorder 
Pain results in control Other results 
8 Arthritis 
Back pain 
Chronic Pain 
Migraine 
Other 
headache 
Psychogenic 
Neuropathic 
ICD-9-CM based 
on electronic 
patient records 
Total n=96,186 in BD 
sample 
 
Any pain 61.3% 
(n=58,983) 
Arthritis 45.3% (n= 
43,595)  
Back pain 33.5%  
(n= 32,264)  
Chronic pain 3.4%  
(n= 3,316)  
Migraine 4.9%  
(n= 4,677) 
Other Headache 6.7% 
(n= 6,419) 
Psychogenic pain 0.9% 
(n= 833) 
Neuropathic pain 5.4% 
(n= 5,180) 
Total n= 4,247,684 in control 
sample 
 
Any pain 42.3%  
(n= 1,795,600) 
Arthritis 32.2%  
(n= 1,365,901)  
Back pain 17.0% (n= 
721,372) 
Chronic Pain 0.7% (n= 
27,758) 
Migraine 1.1% (n= 46,015) 
Other headache 2.0% (n= 
86,126) 
Psychogenic pain 0.1% (n= 
3,646) 
Neuropathic pain 3.7% (n= 
156,393) 
OR comparing BD and 
controls: 
 
Any pain OR 2.17 (CI 2.14-
2.19)* 
Arthritis OR 1.75 (CI 1.73-
1.77)* 
Back pain OR 2.47 (CI 2.43-
2.50)* 
Chronic Pain OR 5.43 (CI 
5.23-5.63)* 
Migraine OR 4.67 (CI 4.53-
4.82)* 
Other headache OR 3.46 
(CI 3.37-3.55)* 
Psychogenic pain OR 10.17 
(CI 9.43-10.96)* 
Neuropathic pain OR 1.49 
(CI (1.45, 1.53)* 
 
32 Migraine  Physician 
diagnosis 
33.9% (n = 115) had 
migraines 
 
No Control Group Migraine group higher nr of 
psychiatric comorbidity 
(72.6%) vs. non migraine 
group (47.4%) p<0.001 
Migraine group more likely 
anxiety disorder (p<0.001) 
and depressive polarity 
  
Table 2 Results of Pain in included studies  
Study Type of pain  Method of pain 
assessment/ 
ascertainment 
Pain results bipolar 
disorder 
Pain results in control Other results 
33 LBP 
Headache 
Elixhauser 
Comorbidity 
Index 
25.8% (n=919/3557) 
had LBP 
 
19.3% (n=685/3557) 
headaches 
 
13.3% (n=96,201/726,262) 
had LBP 
5.7% (n=41,234/ 726,262) 
headaches 
 
BD more likely to have LBP 
(p<0.0001) and headaches 
(p<0.0001).  
34 Chronic pain 
interfering 
with ADL 
Single item 
question 
46% (n=338/641) had 
chronic pain 
interfering with ADL 
 
No control group  
35 1) migraines 
and 2) body 
aches 
Self-report 4 
point Likert 
scale questions 
rating pain 
during 
depressive 
episode 
68.5% sample (46/67) 
had headaches; 29.9% 
slight, 20.9% 
moderate and 17.9% 
major problem 
 
62.6% sample had 
body aches; 22.4% 
slight, 19.4% 
moderate , and 20.9 
major problems 
 
No control group Current BDRS 
score predicted headaches 
(p = 0.012)  BDRS severity 
not related to body aches 
p=0.3 
  
Table 2 Results of Pain in included studies  
Study Type of pain  Method of pain 
assessment/ 
ascertainment 
Pain results bipolar 
disorder 
Pain results in control Other results 
36 General pain VAS interviewer 
administered to 
assess pain over 
last 6 weeks 
(>40 on VAS). 
Noted severity, 
duration and 
interference 
with ADL 
51.2% (n= 62/121) had 
pain 
Duration of pain 62.5 
(±90.9) months 
Severity 67.5 (±14.9)  
Interference with ADL 
67.7 (±21.2) 
Location of pain: 
Head 66.1%; Neck 
66.1%; Back 74.2%; 
Limbs 67.7%; Joints 
64.5% 
Nr. of pain locations: 
3.44 (±1.46) 
75% of pain 
musculoskeletal 
pathology 
No control group Older age associated with 
pain (OR 1.03 (CI 1.00-1.07) 
 
Sex, education, marital 
status, diagnostic group, 
depressed mood, sleep 
disorders and depression 
not related to pain.   
37 Painful 
somatic 
symptoms 
 
Medical records  22.6% (n=56/248) No control group  
38 General pain 
interfering 
with activities 
Single item 
question about 
pain interfering 
with ADL over 
past 4 weeks (0-
not at all to 5 
extremely)  
24.8% (n=219/883) 
had moderate or 
worse pain interfering 
with ADL  
11.9% (n=5023/ 42,210) had 
moderate or worse pain 
interfering with ADL 
P<0.001 
Comorbid anxiety (OR 1.72, 
95% CI 1.41–2.10), being 
married (OR 1.33, 95% CI 
1.08–1.64) and SUD (OR 
1.91, 95% CI 1.56–2.34) 
associated with interfering 
pain. Age, lower income 
associated with pain 
(p<0.001). 
Table 2 Results of Pain in included studies  
Study Type of pain  Method of pain 
assessment/ 
ascertainment 
Pain results bipolar 
disorder 
Pain results in control Other results 
39 Migraine Unclear, 
searched 
patient records 
 
4.7% (n=8/169) No control group  
40 Migraine/ 
headache 
ICHD-2 70% (n=7/10) had 
migraine 
 
No control group  
41 LBP LBP classified as 
present yes/ no 
from national 
patient 
electronic 
records 
database 
 
15.4% (n=663/4310) 
had LBP 
10.6% 
(n=361,868/3,408,760) 
P<0.0001  
BD more likely to have LBP 
(p<0.0001) 
42 Migraine Question on 
lifetime 
prevalence of 
migraine 
 
39.8% (n=43/108) had 
lifetime prevalence of 
migraine 
No control group Number of psychiatric 
admission higher in BD 
without migraine (p=.046), 
no difference in suicide 
attempts or SUD 
43 Migraine/ 
headache 
Physician 
diagnosed and 
classified 
20% (n=6/30) migraine 
 
33.3% (n=10/30) 
muscle tension 
headache 
 
No control group  
44 Migraine Survey on 
previous 
diagnosis by 
physician 
14.9% for males 
and 34.7% for females 
had migraines 
5.8% for men and 14.7% 
females had migraines 
BD males with migraine 
more likely to report earlier 
BD onset (p<.05), and 
anxiety (p<.05).  
Table 2 Results of Pain in included studies  
 
Study Type of pain  Method of pain 
assessment/ 
ascertainment 
Pain results bipolar 
disorder 
Pain results in control Other results 
45 Arthritis/ 
chronic pain 
Single item self-
report question 
48.9% (n=188/384) 
had chronic pain 
 
No control group Chronic pain associated 
with worse physical HRQOL 
(p<0.001) but better 
mental HRQOL scores 
(p=0.01) 
 
46 Joint pain Check list 18.5% (n=5/27) had 
joint pain 
No control group  
47 Migraine ID migraine 
questionnaire 
according to 
International 
Headache 
Society 
 
23.9% (n=71/296) had 
migraine 
No control group Migraine associated with 
BD diagnostic subtype 
(p<0.001), History suicidal 
behaviour (p=.03), social 
phobia 7 panic disorder 
(p<.001), OCD and anxiety 
(p<.001) 
48 Medically 
unexplained 
pain (MUS) 
Asked if has 
pain lasting 
>6 months in 
past year that 
was severe/ 
interfered with 
ADL and could 
not be 
explained.  
 
0.3% had severe 
chronic pain 
interfering with ADL 
(n=190/6328) 
OR 5.93 (1.71–20.60)  
No control group data  
49 Chronic pain GP database 
≥4 analgesic 
prescriptions in 
17.5% (n=451/2582) 
Had chronic pain 
8.8% (n=125,680/ 1,421,796) 
had chronic pain 
 
OR 1.88 P <0.001 
Chronic pain in BD vs. 
control 
Table 2 Results of Pain in included studies  
last year OR ≥4 
antiepileptics in 
the absence 
of an epilepsy 
 
Study Type of pain  Method of pain 
assessment/ 
ascertainment 
Pain results bipolar 
disorder 
Pain results in control Other results 
50 Chronic pain Modified CIDI 
checklist for 
medical 
disorders 
 
 
40.4% (n=38/93) had 
chronic pain 
Not reported BD associated with chronic 
pain OR 3.0(CI 1.5-5.8) 
p<0.001* 
51 General pain Classified from 
medical records 
present =yes/ 
no 
18.1% had pain 
(n=4381/24206) 
No control group  
52 Migraine Defined from 
medical records 
2.0% migraine 
(n=530/27,054) 
0.7% (n=16,383/2,325,247)  
Key: BD= bipolar disorder, VAS = visual analogue scale, ADL=activities of daily living, ICHD-2=International Classification of Headache Disorders, 2nd edition, 
LBP=low back pain, SF 36= short form 36, nr=number, SUD= substance use disorder, BDRS = Bipolar Depression Rating Scale, OCD=obsessive compulsive 
disorder 
 
Figure 1. PRISMA 2009 flow diagram for search strategy 
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Additional records identified 
through other sources 
(N=4) 
Records after duplicates removed  
(N = 2,319) 
Records screened  
(N = 460) 
Records excluded  
(N = 388) 
Full-text articles assessed 
for eligibility  
(N = 72) 
Full-text articles excluded (n=50), 
with reasons: 
N=22 did not report pain 
prevalence/ measure pain 
N=10 not persons with bipolar 
disorder 
N=6 not relevant 
N=5 contacted authors to 
request data for inclusion but no 
response 
N=2 selection bias/ not 
representative 
N=2 overlap 
N=2 case studies 
N=1 contacted authors and 
exclude as meet exclusion 
criteria 
 
Studies included in 
narrative synthesis  
(N=22: 
BPD n= 171,352 and 
control n= 12,204,292)) 
Records excluded on title 
abstract level  
(N = 1859) 
Figure 2: Random effects pooled prevalence of pain in bipolar samples (N=22, n= 171,352) 
 
Pooled proportion = 28.9% (95% CI = 16.4 - 43.4%) 
Cochran Q = 66988.29 (df = 24) P < 0.0001 
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Figure 2: Random effects pooled prevalence of pain in bipolar samples (N=22, n= 171,352) 
Figure 2b Funnel plot 
 
Begg-Mazumdar: Kendall's tau = -0.013, P = 0.90 
Egger: bias = 11.510, P = 0.48 
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Figure 3 Relative risk of pain in people with bipolar disorder compared to controls (N=7, 
n=12,342,577) 
 
 
Pooled relative risk = 2.14 (95% CI = 1.676 - 2.75), Chi squared= 36.623  (df = 1) P < 0.0001 
Cochran Q = 1078.49 (df = 7)  P < 0.0001 
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